Literature DB >> 19616561

(-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway.

Sean A Hudson1, Heath Ecroyd, Francis C Dehle, Ian F Musgrave, John A Carver.   

Abstract

The polyphenol (-)-epigallocatechin-3-gallate (EGCG) has recently attracted much research interest in the field of protein-misfolding diseases because of its potent anti-amyloid activity against amyloid-beta, alpha-synuclein and huntingtin, the amyloid-fibril-forming proteins involved in Alzheimer's, Parkinson's and Huntington's diseases, respectively. EGCG redirects the aggregation of these polypeptides to a disordered off-folding pathway that results in the formation of non-toxic amorphous aggregates. Whether this anti-fibril activity is specific to these disease-related target proteins or is more generic remains to be established. In addition, the mechanism by which EGCG exerts its effects, as with all anti-amyloidogenic polyphenols, remains unclear. To address these aspects, we have investigated the ability of EGCG to inhibit amyloidogenesis of the generic model fibril-forming protein RCMkappa-CN (reduced and carboxymethylated kappa-casein) and thereby protect pheochromocytoma-12 cells from RCMkappa-CN amyloid-induced toxicity. We found that EGCG potently inhibits in vitro fibril formation by RCMkappa-CN [the IC(50) for 50 microM RCMkappa-CN is 13+/-1 microM]. Biophysical studies reveal that EGCG prevents RCMkappa-CN fibril formation by stabilising RCMkappa-CN in its native-like state rather than by redirecting its aggregation to the disordered, amorphous aggregation pathway. Thus, while it appears that EGCG is a generic inhibitor of amyloid-fibril formation, the mechanism by which it achieves this inhibition is specific to the target fibril-forming polypeptide. It is proposed that EGCG is directed to the amyloidogenic sheet-turn-sheet motif of monomeric RCMkappa-CN with high affinity by strong non-specific hydrophobic associations. Additional non-covalent pi-pi stacking interactions between the polyphenolic and aromatic residues common to the amyloidogenic sequence are also implicated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616561     DOI: 10.1016/j.jmb.2009.07.031

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  33 in total

1.  Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols.

Authors:  Ping Cao; Daniel P Raleigh
Journal:  Biochemistry       Date:  2012-03-21       Impact factor: 3.162

2.  A multi-pathway perspective on protein aggregation: implications for control of the rate and extent of amyloid formation.

Authors:  Damien Hall; József Kardos; Herman Edskes; John A Carver; Yuji Goto
Journal:  FEBS Lett       Date:  2015-01-31       Impact factor: 4.124

3.  Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286).

Authors:  Nataliya Popovych; Jeffrey R Brender; Ronald Soong; Subramanian Vivekanandan; Kevin Hartman; Venkatesha Basrur; Peter M Macdonald; Ayyalusamy Ramamoorthy
Journal:  J Phys Chem B       Date:  2012-03-07       Impact factor: 2.991

4.  Alternative pathways of human islet amyloid polypeptide aggregation distinguished by (19)f nuclear magnetic resonance-detected kinetics of monomer consumption.

Authors:  Yuta Suzuki; Jeffrey R Brender; Kevin Hartman; Ayyalusamy Ramamoorthy; E Neil G Marsh
Journal:  Biochemistry       Date:  2012-10-01       Impact factor: 3.162

5.  NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG.

Authors:  Rui Huang; Subramanian Vivekanandan; Jeffrey R Brender; Yuki Abe; Akira Naito; Ayyalusamy Ramamoorthy
Journal:  J Mol Biol       Date:  2011-12-17       Impact factor: 5.469

6.  How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro.

Authors:  Nikolai Lorenzen; Søren B Nielsen; Yuichi Yoshimura; Brian S Vad; Camilla Bertel Andersen; Cristine Betzer; Jørn D Kaspersen; Gunna Christiansen; Jan S Pedersen; Poul Henning Jensen; Frans A A Mulder; Daniel E Otzen
Journal:  J Biol Chem       Date:  2014-06-06       Impact factor: 5.157

7.  The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity.

Authors:  Fanling Meng; Andisheh Abedini; Annette Plesner; C Bruce Verchere; Daniel P Raleigh
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

Review 8.  Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity.

Authors:  Ping Cao; Peter Marek; Harris Noor; Vadim Patsalo; Ling-Hsien Tu; Hui Wang; Andisheh Abedini; Daniel P Raleigh
Journal:  FEBS Lett       Date:  2013-02-01       Impact factor: 4.124

Review 9.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

10.  Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.

Authors:  Yan Xu; Yanyan Zhang; Zhenzhen Quan; Winnie Wong; Jianping Guo; Rongkai Zhang; Qinghu Yang; Rongji Dai; Patrick L McGeer; Hong Qing
Journal:  Neurochem Res       Date:  2016-06-30       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.